Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial.

Trial Profile

Varenicline, an Alpha 4 Beta 2 Nicotinic Acetylcholine Receptor Partial Agonist, on Cognitive Dysfunction in 120 Patients With Schizophrenia: a Randomized, Double Blind, 8 Weeks Trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Varenicline (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2016 Results (n=60), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 08 Feb 2012 Primary endpoint 'Cognitive-function-tests' has not been met (3066936).
    • 08 Feb 2012 Primary endpoint 'Continuous-Performance-Test' has been met (3066936).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top